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In Japan, information of daily airborne Japanese cedar pollen counts is made public 
during pollen season.  If symptoms severity and treatment outcome are predictable 
according to these pollen counts, management of seasonal allergic rhinitis may become 
more precise. 
Aims of the study  
To evaluate the relationship between airborne pollen counts, symptoms severity and 
treatment outcome in Japanese cedar pollinosis patients. 
Methods  
In the randomized study, patients with moderate to most severe Japanese cedar 
pollinosis were treated with fexofenadine (60 mg BD) or fexofenadine and nasal 
corticosteroids for 2 weeks.  During the same period daily airborne pollen counts were 
measured. 
Results 
One hundred and five adult patients were enrolled.  No difference of treatment efficacy 
was seen among groups.  Detailed results of efficacy & safety were previously 
described elsewhere.  In univariate analysis, the mean cumulated amount of airborne 
pollen exposure for 4 days prior to the study tended to affect symptoms severity 
(p=0.053) and the mean cumulated amount of airborne pollen during the treatment 
period tended to show difference among five treatment outcome categories (p=0.066).  
In multivariate analysis, the mean cumulated amount of airborne pollen exposure for 4 
days prior to the study was identified as only significant factor of symptoms severity 
(p=0.0327) and cumulated amount of airborne pollen during the treatment period 
(p=0.027) and allergic history (p=0.027) were significant factors of treatment outcomes.  
No serious adverse effect was reported during the study. 
 
Conclusions 
The amount of airborne pollen may be predictive of both symptoms severity and 
treatment outcome. 
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Japanese cedar pollinosis is a very common disorder in Japan where 
its prevalence is estimated to be approximately 16% (1).  Although a 
relationship of nasal mucosal sensitivity to allergens is suggested, the 
reasons for variation of symptom severity and differing response to 
treatment are poorly understood (2, 3).  Difference of individual pollen 
burden may be responsible for the treatment outcome.  In Japan, 
information on daily airborne Japanese cedar pollen counts is made 
public by many different government authorities, universities and 
private institutions in each area.  The clinical use of such information is 
poorly understood.  If symptom severity and treatment outcome are 
predictable according to daily exposure to pollen count, management of 
seasonal allergic rhinitis may become more precise. 
This is a sub-analysis of an efficacy study comparing fexofenadine 
monotherapy with fexofenadine and nasal corticosteroids to determine 
the relationship of airborne pollen counts to symptom severity and 
treatment outcome in Japanese cedar pollinosis patients (4). 
 
Patients and Methods 
 
A prospective, open-label, randomized, observational study in adult 
patients with Japanese cedar pollinosis was conducted in 3 different 
areas (Nagasaki, Sasebo and Tagawa area) of Kyushu, Japan.  Patient 
inclusion or exclusion criteria and study design have previously been 
described (4).  Briefly, patients with moderate to most severe disease 
assessed according to practical guidelines for the management of 
allergic rhinitis in Japan were enrolled (5).  Symptom severity was 
assessed by number of episode of sneezing and rhinorrhea and state of 
nasal obstruction.  Patients with mild disease were excluded as good 
response to treatment is expected in these patients. Patients were 
randomized to treatment with fexofenadine 60 mg BD alone or 
fexofenadine 60 mg BD and concurrent nasal corticosteroids (there was 
no restriction on the type or dose).  After one week, patients who had 
poor response to treatment with fexofenadine alone were given 
additional nasal corticosteroids.  At the end of two weeks, response to 
treatment was assessed by the physician in agreement with the 
Japanese guideline (5).  In each area, a Durham pollen collector was 
used for measuring the amount of airborne pollen.  The study was 
approved by the ethics committee at each participating hospital and 




The correlation between the cumulative amount of airborne pollen 
during the 4 days prior to the first physician visit and symptom severity 
was evaluated using Pearson’s product moment correlation coefficient.  
The correlation between the cumulative amount of airborne pollen to 
which patient was exposed during treatment and the treatment 
outcome was evaluated using least mean–square estimation with 
mixed effects models.  The trends of daily airborne pollen counts in 
patients with or without favorable treatment outcome were evaluated 
by least mean-square estimation.  In addition, multivariate analysis 
was performed regarding symptom severity and treatment outcomes.  
As no difference was seen in efficacy between treatment groups, all 
patients were included in the assessment for relationship of pollen 
count with treatment outcome.  Combining all treatment arms is 




Between February 16 and March 31 2006, 138 patients were enrolled.  
One hundred and five patients (85 males and 20 females, mean age: 
41.7 years) had data for pollen count assessment. Moderate (34%), 
severe (52%) and most severe (14%) seasonal allergic rhinitis was 
diagnosed. 
 
1.  Treatment outcome 
Forty patients were treated with fexofenadine monotherapy for 2 
weeks.  Eleven patients were treated with fexofenadine monotherapy 
for 1 week and nasal corticosteroids were added in the second week.  
The other 54 patients were treated with combination therapy of 
fexofenadine and nasal corticosteroid for 2 weeks. 
At the end of week one, no significant difference of treatment efficacy 
was seen between 51 patients who started with fexofenadine 
monotherapy and 54 patients started to treat with combination therapy.  
At the end of the study, although additional one-week treatment of 
nasal corticosteroid was effective in 11 patients who had shown 
insufficient improvement, no significant difference of treatment efficacy 
was seen between the two groups (4).  Patients with moderate to 
severe cedar pollinosis benefit from combination therapy with 
fexofenadine and a nasal corticosteroid as initial treatment.  However, 
using an alternative approach of fexofenadine monotherapy as initial 
treatment and then followed by nasal corticosteroids as needed 
resulted in similar efficacy, sparing most patients unnecessary steroid 
exposure.  After 2 weeks of treatment, response was judged by 
physicians as excellent (12 patients), very good (43 patients), good (35 
patients), poor (9 patients) and inefficient (6 patients). 
   
2. The amount of airborne Japanese cedar pollen  
The cumulative amount of airborne cedar pollen in the Nagasaki, 
Sasebo and Tagawa areas during the study was 2,154, 1,747 and 3,553 
grains/cm2, respectively.  In each area, exposure to airborne pollen 
was observed with an approximately 4-day cycle. Mean daily counts are 
shown in Figure 1.  In patients with moderate, severe, or most severe 
seasonal allergic rhinitis, the mean cumulative amount of airborne 
pollen 4 days prior to the first physician’s visit was 62, 88, 91 
grains/cm2, respectively.  Among these three categories of symptom 
severity, a trend (p=0.053) was observed in terms of pollen count 
(Figure 2).  The sum of airborne Japanese cedar pollen exposure over 
the 2 week treatment period was compared in each treatment outcome 
category.  As shown in Figure 3, the mean cumulative amount of 
airborne pollen in patients whose response to treatment was classified 
as excellent, very good, good, poor and inefficient was 1,025, 1,093, 
1,031, 1,544 and 1,380 grains/cm2, respectively, indicating a tendency 
among groups (p=0.066).  Daily changes in the amount of airborne 
cedar pollen in patients who improved (classified as excellent and very 
good) were compared with daily changes in patients who did not 
improve (classified as poor and inefficient) (Figure 4).  The daily 
changes of airborne cedar pollen in patients who did not improved 
sustained a significantly higher trend than those in patients who 
improved (p=0.0004).  
In multivariate analysis, only the mean cumulative amount of 
airborne pollen exposure 4 days prior to the first physician’s visit was 
identified as significant factor of disease severity (p=0.0327).  Gender, 
age, disease type, duration of illness and presence or absence of allergy 
history were not implicated in symptom severity.  The mean 
cumulative amount of airborne pollen during the treatment period and 
history of allergy were significant factors for treatment outcome 
(p=0.027 and 0.027, respectively).  Symptom severity was not a 
significant factor of treatment outcome (p=0.416). 
  
3．Safety 
All study medications were well tolerated.  No serious adverse 




This study is the first study to assess the relationship of airborne 
pollen counts to disease severity and treatment outcome in Japanese 
sufferers of cedar pollinosis.  Our study addressed two questions: 1) 
does the cumulative amount of airborne pollen just prior to the 
physician’s visit affect disease severity at the diagnosis?  2) Does the 
total airborne pollen amount during treatment affect treatment 
response?   
Our result shows that airborne pollen burden may affect symptom 
severity.  In multivariate analysis, the mean cumulative amount of 
airborne pollen 4 days prior to the first physician’s visit was the only 
factor identified as having significant effect on symptom severity for 
patients with moderate to most severe disease.  Baba et al. reported 
that frequency of patients who complain of symptoms of rhinitis 
correlates well with the square root of the cumulative amount of daily 
airborne pollen from the first day of exposure in the pollen season (2, 
6).  
 Is nasal mucosal sensitivity to airborne pollen responsible for 
symptom severity?  Baba et al. also reported that there are two 
different types of sensitivity to pollen in pollinosis patients (2, 6).  In 
high-sensitivity type patients, their symptoms appear earlier even at 
low daily amounts of airborne pollen.  On the other hand, symptoms 
appear gradually in low-sensitivity type patients.  The mechanism of 
the difference in sensitivity remains unclear.  No correlation was found 
between overall frequencies of in vivo sensitization to tree pollen 
allergens in a local population and regional pollen exposure data (7). 
In addition, our results show that the mean cumulative amount of 
airborne pollen during the treatment period and history of allergy were 
significant factors for positive treatment outcome in multivariate 
analysis.  Our data indicate that patients who were exposed to larger 
amounts of daily airborne pollen were less responsive to treatment.  
The amount of airborne pollen plays an important role in treatment 
response, although nasal mucosal sensitivity may also affect treatment 
outcome.  Expectations for treatment outcome cannot be determined 
based on the amount of daily airborne pollen at the beginning of the 
treatment.  Although the daily amount of airborne cedar pollen 
changes, patients with the same cumulative amount have a different 
daily amount of airborne pollen.  Therefore, the daily change rather 
than cumulative amount to which a patient is exposed may be more 
responsible for the treatment outcome. 
In multivariate analysis, symptom severity was not a significant 
factor of treatment outcome.  Degree of symptom severity of Japanese 
cedar pollinosis fluctuates according to the exposed amount of airborne 
cedar pollen, although treatment modality is decided based on 
symptom severity when seeing a doctor.  Therefore, our results 
suggest that treatment outcome of Japanese cedar pollinosis is more 
affected on daily degree of exposure to cedar pollen than symptom 
severity when seeing a doctor.  
What can we learn from the daily amount of airborne pollen?  
Throughout Japan, there are more than 200 facilities measuring 
airborne pollen.  Our data show that the amount of airborne pollen is 
predictive of symptom severity, although patients with mild type 
seasonal allergic rhinitis were not included in this study.  Retrospective 
data suggest a relationship between pollen counts and treatment 
outcome.  Actual and expected information of regional pollen counts 
may be helpful for the management of seasonal allergic rhinitis in 
addition to reduction of patients’ chance of exposure to pollen antigen. 
In conclusion, this is the first study to show that symptom severity 
and treatment outcome may be partially affected by the daily burden of 
airborne pollen.  Impact of different factors such as individual 
sensitivity to pollen allergens may have less of an impact on the 
management of seasonal allergic rhinitis. 
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Figure Legend 
Figure 1.  Trends of airborne pollen counts in 3 areas. 
 
Figure 2.  The relationship between symptom severity and cumulative 
airborne pollen amounts 4 days prior to the first physician visit.  Bar 
indicates mean ± SD. 
 
Figure 3.  The relationship between treatment outcomes and 
cumulative airborne pollen throughout the 2 week treatment period. 
Bar indicates mean ± SD.  p=0.066 
 
Figure 4.  Daily trends of airborne pollen from 4 days prior to first 
physician visit to the end of study. 
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